17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

      Nature medicine
      Animals, Antidiuretic Hormone Receptor Antagonists, Aquaporin 2, Aquaporin 6, Aquaporins, genetics, metabolism, Benzazepines, therapeutic use, Cyclic AMP, Disease Models, Animal, Disease Progression, Humans, Kidney, pathology, Mice, Polycystic Kidney Diseases, drug therapy, physiopathology, Proteins, Rats, Rats, Sprague-Dawley, Receptors, Vasopressin, TRPP Cation Channels

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The polycystic kidney diseases (PKDs) are a group of genetic disorders causing significant renal failure and death in children and adults. There are no effective treatments. Two childhood forms, autosomal recessive PKD (ARPKD) and nephronophthisis (NPH), are characterized by collecting-duct cysts. We used animal models orthologous to the human disorders to test whether a vasopressin V2 receptor (VPV2R) antagonist, OPC31260, would be effective against early or established disease. Adenosine-3',5'-cyclic monophosphate (cAMP) has a major role in cystogenesis, and the VPV2R is the major cAMP agonist in the collecting duct. OPC31260 administration lowered renal cAMP, inhibited disease development and either halted progression or caused regression of established disease. These results indicate that OPC31260 may be an effective treatment for these disorders and that clinical trials should be considered.

          Related collections

          Author and article information

          Comments

          Comment on this article